Identifying real differences in live birth rates between HMG and rFSH in IVF

Afnan, 2007, Statistically significant increase in live births with hMG in IVF and ICSI cycles versus rFSH: results from a systematic review, Human Reproduction, 22, i39 Al-Inany, 2008, Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis, Reproductive BioMedicine Online, 16, 81, 10.1016/S1472-6483(10)60559-7 Andersen, 2006, Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial, Human Reproduction, 21, 3217, 10.1093/humrep/del284 Andersen, 2004, FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect?, Reproductive BioMedicine Online, 9, 231, 10.1016/S1472-6483(10)62135-9 Arce, 2006, Impact of hCG levels in the mid-follicular phase during treatment with highly purified menotrophin on embryo quality and outcome in IVF cycles, Human Reproduction, 21, i141 Balasch, 2003, Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction, Reproductive BioMedicine Online, 7, 35, 10.1016/S1472-6483(10)61726-9 Chalmers, 1993, The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care, Annals of the New York Academy of Sciences, 703, 156, 10.1111/j.1749-6632.1993.tb26345.x Cook, 1995, The number needed to treat: a clinically useful measure of treatment effect, British Medical Journal, 310, 452, 10.1136/bmj.310.6977.452 Coomarasamy, 2008, Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis, Human Reproduction, 23, 310, 10.1093/humrep/dem305 de Koning, 2006, The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles, Human Reproduction, 21, 443, 10.1093/humrep/dei317 Dickey, 2004, What is the most relevant standard of success in assisted reproduction?: no single outcome measure is satisfactory when evaluating success in assisted reproduction; both twin births and singleton births should be counted as successes, Human Reproduction, 19, 783, 10.1093/humrep/deh181 Egger, 1997, Meta-analysis. Potentials and promise, British Medical Journal, 315, 1371, 10.1136/bmj.315.7119.1371 European and Israeli Study Group, 2002, Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in-vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial, Fertility and Sterility, 78, 520, 10.1016/S0015-0282(02)03250-8 Gordon, 2001, A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in-vitro fertilization outcome, Fertility and Sterility, 75, 324, 10.1016/S0015-0282(00)01701-5 Guyatt, 2002 Higgins Ho, 2003, The effect of preincubation period of oocytes on nuclear maturity, fertilization rate, embryo quality, and pregnancy outcome in IVF and ICSI, Journal of Assisted Reproduction and Genetics, 20, 358, 10.1023/A:1025476910771 Hompes, 2008, Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in-vitro fertilization-intracytoplasmic sperm injection patients, Fertility and Sterility, 89, 1685, 10.1016/j.fertnstert.2007.05.039 Isiklar, 2004, Impact of oocyte pre-incubation time on fertilization, embryo quality and pregnancy rate after intracytoplasmic sperm injection, Reproductive BioMedicine Online, 8, 682, 10.1016/S1472-6483(10)61649-5 Jansen, 1998, A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients, Human Reproduction, 13, 2995, 10.1093/humrep/13.11.2995 Kilani, 2003, A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes, Human Reproduction, 18, 1194, 10.1093/humrep/deg252 Kovalevsky, 2005, High rates of embryo wastage with use of assisted reproductive technology: a look at the trends between 1995 and 2001 in the United States, Fertility and Sterility, 84, 325, 10.1016/j.fertnstert.2005.04.020 Lin, 2007, Follitropin receptors contain cryptic ligand binding sites, Molecular and Cellular Endocrinology, 260–262, 83, 10.1016/j.mce.2006.06.012 Magier, 1990, Significance of cumulus oophorus in in-vitro fertilization and oocyte viability and fertility, Human Reproduction, 5, 847, 10.1093/oxfordjournals.humrep.a137196 Ng, 2001, HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial, Human Reproduction, 16, 319, 10.1093/humrep/16.2.319 Patrizio, 2007, High rate of biological loss in assisted reproduction: it is in the seed, not in the soil, Reproductive BioMedicine Online, 14, 92, 10.1016/S1472-6483(10)60769-9 Perez Mayorga, 2000, Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype, Journal of Clinical Endocrinology and Metabolism, 85, 3365, 10.1210/jc.85.9.3365 Platteau, 2008, Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles, Reproductive BioMedicine Online, 17, 190, 10.1016/S1472-6483(10)60194-0 Platteau, 2004, Exogenous luteinizing hormone activity may influence the treatment outcome in in-vitro fertilization but not in intracytoplasmic sperm injection cycles, Fertility and Sterility, 81, 1401, 10.1016/j.fertnstert.2003.09.077 Rashidi, 2005, The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 120, 190, 10.1016/j.ejogrb.2004.11.007 Rienzi, 1998, Preincubation of human oocytes may improve fertilization and embryo quality after intracytoplasmic sperm injection, Human Reproduction, 13, 1014, 10.1093/humrep/13.4.1014 Smitz, 2007, Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients, Human Reproduction, 22, 676, 10.1093/humrep/del445 Stewart, 1995, Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group, Statistics in Medicine, 14, 2057, 10.1002/sim.4780141902 Van Wely, 2003, Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles, Cochrane Database of Systematic Reviews Westergaard, 2001, Fertility and Sterility, 76, 543, 10.1016/S0015-0282(01)01973-2 Wolfenson, 2005, Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations, Reproductive BioMedicine Online, 10, 442, 10.1016/S1472-6483(10)60819-X